Stockreport

MBX Biosciences (MBX) Is Up 84.0% After Positive Phase 2 Results for Canvuparatide - Has The Bull Case Changed? [Yahoo! Finance]

MBX Biosciences, Inc.  (MBX) 
PDF achieving the primary endpoint with statistical significance and a high responder rate at 6 months in adults with chronic hypoparathyroidism. An impressive 94% of pati [Read more]